Filtered By:
Infectious Disease: Pandemics
Drug: Oseltamivir

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 215 results found since Jan 2013.

Experts with links to drugs industry 'hyped swine flu'
Conclusion This was a well-conducted study, albeit based on a small sample of articles. The finding that academics with ties to the drugs industry were more likely to make a higher assessment of risk from swine flu, and those promoting the use of antiviral drugs were more likely to have industry links, is worrying. The general issue of academics with undisclosed links to the pharmaceutical industry being interviewed by journalists is of concern. That said, the study does not prove that media coverage either fuelled public anxiety about swine flu or the policy decisions made about drug or vaccine funding. Similarly, the...
Source: NHS News Feed - November 12, 2013 Category: Consumer Health News Tags: Medical practice Medication Swine flu Source Type: news

Rhinoviruses as an underestimated cause of influenza‐like illness in pregnancy during the 2009–2010 influenza pandemic
The objectives of the study were to identify viruses which could induce an influenza‐like illness in pregnant women during the 2009–2010 pandemic, then to establish possible links between detected viruses and symptoms, and then characterize human rhinoviruses (HRV) strains detected in some samples. Nasal swabs from 78 pregnant women presenting with influenza‐like illness and previously tested for influenza virus by RT‐PCR in 2009–2010 were further assayed by multiplex RespiFinder assay and bocavirus PCR to search for 13 other viruses. Genotyping of HRV strains was carried out using partial genomic sequencing in t...
Source: Journal of Medical Virology - May 30, 2013 Category: Virology Authors: Léa Pilorgé, Mélanie Chartier, Jean‐François Méritet, Minerva Cervantes, Vassilis Tsatsaris, Odile Launay, Flore Rozenberg, Anne Krivine Tags: Research Article Source Type: research

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
CONCLUSIONS: Oseltamivir and zanamivir have small, non-specific effects on reducing the time to alleviation of influenza symptoms in adults, but not in asthmatic children. Using either drug as prophylaxis reduces the risk of developing symptomatic influenza. Treatment trials with oseltamivir or zanamivir do not settle the question of whether the complications of influenza (such as pneumonia) are reduced, because of a lack of diagnostic definitions. The use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children. The lower bioava...
Source: Sao Paulo Medical Journal - July 24, 2014 Category: Journals (General) Authors: Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson M, Spencer EA, Onakpoya I, Mahtani KR, Nunan DN, Howick J, Heneghan CJ Tags: Sao Paulo Med J Source Type: research

Clinical characteristics and outcomes in children hospitalised with pandemic influenza A/H1N1/09 virus infection - a nationwide survey by the Pediatric Infectious Diseases Group of Switzerland.
CONCLUSIONS: Although pandemic influenza A/H1N1/09 virus infection in children is mostly mild, it can be severe, regardless of past history or underlying disease. PMID: 26217892 [PubMed - as supplied by publisher]
Source: Swiss Medical Weekly - July 31, 2015 Category: Journals (General) Authors: Hagerman A, Posfay-Barbe KM, Duppenthaler A, Heininger U, Berger C, The Pigs Influenza Study Group - Tags: Swiss Med Wkly Source Type: research

Emergence of influenza A (H1N1) PDM09 in the remote Islands of India - A molecular approach
Conclusion: A (H1N1) PDM09 Influenza outbreak have highlighted the need to strengthen the region-specific pandemic preparedness plans and surveillance strategies.
Source: Indian Journal of Medical Microbiology - January 5, 2015 Category: Microbiology Authors: N MuruganandamD BhattacharyaIK ChaaithanyaH BhattacharyaR ReesuA MaileGSJ BharathiAP SugunanP Vijayachari Source Type: research

Experts call for tests on use of flu drugs in pandemic
Report says there is a lack of good data on how well Tamiflu works in the community, after missed opportunity during swine flu outbreakNew trials are urgently needed to establish whether the anti-flu drug Tamiflu would help save lives in a pandemic, experts have said.Flu pandemics are highly dangerous, with the potential to kill millions around the world. Each winter in the UK, hundreds die of flu. Yet the drugs available to treat people, of which the best known and most widely used is Tamiflu, appear to have only a modest effect and have only been tested on seasonal flu, according to a report by the Academy of Medical Sci...
Source: Guardian Unlimited Science - October 7, 2015 Category: Science Authors: Sarah Boseley Health editor Tags: Flu Health Pharmaceuticals industry Medical research Society Science UK news Source Type: news

Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): A meta-analysis
Conclusion The results of our study indicated that the mean time to defervescence in the TCM treatment group was less than noted in the control group, and that the duration of viral [Influenza A (H1N1)] shedding in the integrated Chinese and Western medicine subgroups was less than that noted in the control group. However, the available evidence does not consider the fact that the difference in duration of viral shedding and effective rate between the two groups was statistically similar. No obvious adverse events were reported in the included studies.
Source: Journal of the Chinese Medical Association - February 28, 2016 Category: Journals (General) Source Type: research

Comparative Characteristics of the 2009 Pandemic Influenza A (H1N1) Virus and 2010-2011 Seasonal Influenza in Pediatric Patients.
CONCLUSIONS: The type of influenza had no effect on outcome. There were no significant differences between groups in the percentages of in-hospital mortality, admission to intensive care units, prolonged hospitalization (> 9 days), or the development of complications during hospitalization. PMID: 28457075 [PubMed - in process]
Source: The Israel Medical Association Journal - May 1, 2017 Category: Journals (General) Tags: Isr Med Assoc J Source Type: research

Genetic characterisation of influenza A(H1N1)pdm09 viruses circulating in Assam, Northeast India during 2009 & #8211;2015
Conclusions: Regular molecular surveillance of influenza A(H1N1)pdm09 is important to monitor the viral behavior in terms of increase virulence, drug resistance pattern and emergence of novel strains.
Source: Indian Journal of Medical Microbiology - August 15, 2019 Category: Microbiology Authors: Dipankar Biswas Mousumi Dutta Kimmi Sarmah Kaushal Yadav Manika Buragohain Kishore Sarma Biswajyoti Borkakoty Source Type: research

Genetic sequencing of influenza A (H1N1) pdm09 isolates from South India, collected between 2011 and 2015 to detect mutations affecting virulence and resistance to oseltamivir
Conclusion: In this study, although H274Y mutation associated with oseltamivir resistance has not been noted, significant mutations have been noted in both HA and NA genes including D239N, N295S, V106I, Q136K, N248D, V267A. In both HA and NA gene analysis, multiple mutations were found more in 2015 strains when compared to 2012 strains. Hence such accumulation of mutations has to be monitored continuously to determine the efficacy of annual flu vaccines and anti-influenza drugs.
Source: Indian Journal of Medical Microbiology - November 4, 2020 Category: Microbiology Authors: P Nandhini Sujatha Sistla Source Type: research

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Media News - January 12, 2023 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s New Drug Application for Xofluza (baloxavir marboxil) for the treatment of influenza in children
Basel, 27 March  2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) as well as two supplemental New Drug Applications (sNDA) for Xofluza® (baloxavir marboxil). The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and those who have difficulty swallowing. In addition, the application seeks approval of Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged one to l ess than 12 y...
Source: Roche Investor Update - March 27, 2020 Category: Pharmaceuticals Source Type: news

The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology
Conclusions: Human challenge studies and systems biology approaches are important tools that should be used in concert to advance our understanding of influenza infection and provide targets for novel therapeutics and immunizations. Introduction Although influenza virus was recognized as an important pathogen over a century ago, influenza continues to cause a significant burden of disease. In the United States alone, it's estimated that in the 2017–2018 season there were 959,000 hospitalizations related to influenza illness, and 79,400 deaths (CDC, 2018). Worldwide, WHO estimates that annual influen...
Source: Frontiers in cellular and infection microbiology - April 16, 2019 Category: Microbiology Source Type: research

Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person
             Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.“With today’s approval, Xofluza is now available as the first single-dose, post-exposure preventive treatment for influenza,” said Le...
Source: Roche Media News - November 24, 2020 Category: Pharmaceuticals Source Type: news